Clinical trials
Metastatic Pancreatic Cancer clinical trials
Below are recruiting metastatic pancreatic cancer clinical trials, each written for real people, not researchers. We’re tracking 418 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05380414Recruiting
Study of advanced pancreatic cancer using tumor tissue profiles
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
LyonAges 18 years+ - NCT05346536Recruiting
Test blood test for a specific type of pancreatic cancer cell
This trial looks for pancreatic cancer markers in a blood sample (“liquid biopsy”), focusing on cells that show a certain protein (AXL). It may help doctors detect and better track advanced pancreatic cancer before or during first-line treatment.
MontpellierAges 18 years+ - NCT05257993RecruitingPhase 1/Phase 2
Pancreatic cancer trial testing JPI-547 with standard chemo
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
Gyeonggi-doAges 19–79 - NCT04146298RecruitingPhase 1/Phase 2
KRAS-mutant pancreatic cancer T-cell therapy for some people
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
ShanghaiAges 18–75 - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05132244Recruiting
Monitoring blood sugar levels in people starting pancreatic cancer treatment
This study looks at how well blood sugar (glucose) levels can be monitored and managed in people with pancreatic cancer who are starting their first treatment. It aims to understand if careful glucose management can improve well-being and possibly treatment outcomes.
Vancouver, British ColumbiaAges 18 years+ - NCT05093231RecruitingPhase 2
Pembrolizumab plus olaparib for stage 4 pancreatic cancer
This trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a DNA-repair drug) can work better for people with metastatic (stage 4) pancreatic cancer. It targets tumors with certain lab marker results and aims to improve control of cancer growth.
MelbourneAges 18 years+ - NCT05053971RecruitingPhase 1/Phase 2
Entinostat plus ZEN003694 for advanced solid tumors
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
New Haven, ConnecticutAges 18 years+ - NCT05065801RecruitingPhase 2
New metastatic pancreatic cancer: targeted chemo before FOLFIRINOX
This trial tests whether adding Gembrax (a combination that includes gemcitabine and nab-paclitaxel) before standard FOLFIRINOX works better than FOLFIRINOX alone in people with pancreatic cancer that has already spread. It looks at whether this “step-up first” approach improves results and is still tolerable.
Grenoble, Auvergne-Rhône-AlpesAges 18–75 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
Brooklyn, New YorkAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT03977233RecruitingPhase 2
Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Chapel Hill, North CarolinaAges 18–99 - NCT04406831Recruiting
Testing microRNA for pancreatic cancer diagnosis and treatment response
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Norwalk, ConnecticutAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT04048278RecruitingEarly Phase 1
Lidocaine IV infusion for pancreatic cancer treatment
This early-phase study tests whether giving lidocaine through an IV infusion can help treat pancreatic cancer. It will enroll people with confirmed pancreatic cancer that can be measured on scans, including some cases discovered to have spread during surgery.
Chicago, IllinoisAges 18 years+ - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT03823144Recruiting
Imaging small live tumor details during surgery
This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.
Jacksonville, FloridaAges 18 years+ - NCT03608631RecruitingPhase 1/Phase 2
Exosome treatment for KRAS-mutated metastatic pancreatic cancer
This Phase 1/2 study tests an investigational treatment made from “exosomes” for people with metastatic pancreatic cancer that has a specific KRAS mutation (KRAS G12D). It aims to see if this treatment can control the cancer and is safe for patients whose cancer has grown or stayed the same after prior chemotherapy.
Houston, TexasAges 18 years+ - NCT02393703Recruiting
Testing blood signals from tiny cell packets in pancreatic surgery
This study looks at how tiny particles in blood (“exosomes”) carry signals between cells in people having pancreatic surgery. The goal is to understand these signals in different pancreatic conditions and treatment situations, which may help future care.
New York, New YorkAges 18 years+ - NCT01954992RecruitingPhase 3
Glufosfamide vs 5-FU for metastatic pancreatic cancer after gemcitabine
This study compares two chemotherapy drugs—glufosfamide and 5-FU—in people with pancreatic cancer that has spread and got worse after gemcitabine. It aims to see which option works better as a “second-line” treatment.
Whittier, CaliforniaAges 18 years+
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic pancreatic cancer?
- Yes. Clin2 currently lists 418 recruiting metastatic pancreatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic pancreatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic pancreatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.